NextGen - Clinical Implication of Next Generation Sequencing
Part of paid clinical trials in Winston-Salem, North Carolina.
- Sponsor
- Wake Forest University Health Sciences
- Study ID
- NCT05206500
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Urinary Tract Infections
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Antibiotic — DRUGFDA approved and marketed antibiotic treatment for the patients with UTI symptoms and CC \>0 and \<10,000
- Next Gen — DEVICENext Generation Sequencing (NGS) is available to detect bacteria in urine based on bacterial genomes.
Study Details
Recently more advanced techniques, including Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) are available to detect bacteria in urine based on bacterial genomes. Comparing to traditional culture, these techniques have more sensitivity and could potentially be of a great help in patients with Colony Count of less than 10,000 and more than zero.
Key Dates
- Start date
- May 17, 2022
- Status verified
- Dec 2025
- Primary completion
- Dec 31, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Other: Symptomatic Patients with low Colony CountPatients with positive urinalysis, symptomatic, and Urine Culture Colony Count \<10,000 to be treated based on Next Generation Sequencing result.
Primary Outcome Measure
Next Generation Sequencing (NGS) Results (numbers of colony count (CC)) of Urinary Tract Infection (UTI) [ Time Frame: Baseline ]
Central Contacts
- Majid Mirzazadeh, MD336-716-4310
- Sachin N Vyas, MS, PhD336-713-4098
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Wake Forest Health Sciences | Winston-Salem | North Carolina | 27157 | Majid Mirzazadeh, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Winston-Salem, NC
By research site
Related Studies
- A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)PHASE2 · Recruiting · Locus Biosciences · Fresno, California
- Vaginal Ecosystem and Network in the United States StudyEnrolling By Invitation · Vaginal Biome Science · Fullerton, California
- Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility StudyRecruiting · Antonios Likourezos · Brooklyn, New York
- Follow-up Automatically vs. As-Needed Comparison (FAAN-C) TrialRecruiting · University of Utah · Phoenix, Arizona